Trial Profile

A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary) ; Ganaxolone (Primary)
Indications Angelman syndrome; Epilepsy; Fragile X syndrome; Lennox-Gastaut syndrome; Postnatal depression; Status epilepticus
Focus Adverse reactions; Pharmacokinetics

06 Dec 2022 Results presented at the 76th Annual Meeting of the American Epilepsy Society
30 Nov 2022 According to Marinus Therapeutics media release, results from this trial will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting.
11 Oct 2022 According to Marinus Therapeutics media release, the company will present the poster presentation on "Pharmacodynamic study and effects of intravenous Ganaxolone bolus in healthy volunteers" at the 20th Neocritical Care Society Annual Meeting commencing from 17th-21st October 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com